Literature DB >> 32200014

OIP5-AS1 attenuates microangiopathy in diabetic mouse by regulating miR-200b/ACE2.

Wei Xie1, Danni Wu1, Yi Ren1, Ying Jiang1, Hao Zhang1, Song Yang1, Shiying Sheng2.   

Abstract

This study aimed to investigate OIP5-AS1 effects on microangiopathy in diabetic mouse. Our results indicated that diabetic mice exhibited much lower OIP5-AS1 expression in the hippocampus than normal mice. Diabetic mice of OIP5-AS1 KO group showed remarkably lower OIP5-AS1 expression in the hippocampus, longer escape latency and lower percentage of CD31+ cells in the hippocampusthan those of WT group. OIP5-AS1 knockdown directly up-regulated miR-200b expression and ACE2 was directly inhibited by miR-200b. Relative to normal mice, diabetic mice had markedly higher miR-200b expression and lower ACE2 expression in the hippocampus. Diabetic mice of OIP5-AS1 KO group were with obviously higher miR-200b expression and lower ACE2 expression in the hippocampus than those of WT group. Compared with diabetic mice of OIP5-AS1 KO group, those of WT group, OIP5-AS1 KO + miR-200b inhibitor group and OIP5-AS1 KO + ACE2 group had obviously shorter escape latency and higher percentage of CD31+ cells and more caspase-3 protein expression in the hippocampus. In conclusion, OIP5-AS1 attenuated microangiopathy in diabetic mouse by regulating miR-200b/ACE2.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  ACE2; OIP5-AS1; diabetic mouse; miR-200b; microangiopathy

Year:  2020        PMID: 32200014     DOI: 10.1016/j.wneu.2020.03.063

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  7 in total

1.  Angiotensin-converting enzyme 2 inhibits inflammation and apoptosis in high glucose-stimulated microvascular endothelial cell damage by regulating the JAK2/STAT3 signaling pathway.

Authors:  Yi Ren; Wei Xie; Song Yang; Ying Jiang; Danni Wu; Hao Zhang; Shiying Sheng
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Investigation of circulating lncRNAs as potential biomarkers in chronic respiratory diseases.

Authors:  Zsófia Gál; András Gézsi; Ágnes F Semsei; Adrienne Nagy; Monika Sultész; Zsuzsanna Csoma; Lilla Tamási; Gabriella Gálffy; Csaba Szalai
Journal:  J Transl Med       Date:  2020-11-10       Impact factor: 5.531

3.  ACE2 deficiency exacerbates obesity-related glomerulopathy through its role in regulating lipid metabolism.

Authors:  Yin-Yin Che; Han Hong; Yu-Ting Lei; Jia Zou; Yi-Ya Yang; Li-Yu He
Journal:  Cell Death Discov       Date:  2022-09-30

Review 4.  The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.

Authors:  Don A Davies; Aida Adlimoghaddam; Benedict C Albensi
Journal:  Mol Neurobiol       Date:  2021-06-01       Impact factor: 5.590

Review 5.  Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes.

Authors:  Serena Wooten; Keriayn N Smith
Journal:  Clin Transl Med       Date:  2022-01

6.  Angiotensin-(1-7) Analogue AVE0991 Modulates Astrocyte-Mediated Neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 Pathway and Offers Neuroprotection in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Rui Duan; Si-Yu Wang; Bin Wei; Yang Deng; Xin-Xin Fu; Peng-Yu Gong; Yan E; Xiao-Jin Sun; Hai-Ming Cao; Jian-Quan Shi; Teng Jiang; Ying-Dong Zhang
Journal:  J Inflamm Res       Date:  2021-12-18

7.  Long Non-Coding RNAs Expression in Breast Cancer: CBR3-AS1 LncRNA as a Sensitive Biomarker.

Authors:  Safora Torkashvand; Ali Basi; Hossein Ajdarkosh; Nasser Rakhshani; Nahid Nafisi; Seyed Javad Mowla; Ayda Moghadas; Mahshid Mohammadipour; Mohammad Hadi Karbalaie Niya
Journal:  Asian Pac J Cancer Prev       Date:  2021-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.